S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
Log in
NASDAQ:IMMP

Immutep Stock Forecast, Price & News

$2.75
+0.07 (+2.61 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.68
Now: $2.75
$2.81
50-Day Range
$2.68
MA: $3.19
$3.56
52-Week Range
$0.53
Now: $2.75
$7.95
Volume171,981 shs
Average Volume835,775 shs
Market Capitalization$134.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Â'eftilagimod alpha' or Â'efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Immutep logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMMP
CUSIPN/A
Phone61-2-8315-7003
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.92 million
Book Value$0.57 per share

Profitability

Miscellaneous

Market Cap$134.10 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

747th out of 1,966 stocks

Pharmaceutical Preparations Industry

366th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$2.75
+0.07 (+2.61 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immutep (NASDAQ:IMMP) Frequently Asked Questions

Is Immutep a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Immutep stock.
View analyst ratings for Immutep
or view top-rated stocks.

What stocks does MarketBeat like better than Immutep?

Wall Street analysts have given Immutep a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immutep wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Immutep?

Immutep saw a drop in short interest in January. As of January 29th, there was short interest totaling 56,200 shares, a drop of 72.6% from the January 14th total of 204,800 shares. Based on an average trading volume of 6,030,000 shares, the short-interest ratio is currently 0.0 days.
View Immutep's Short Interest
.

How has Immutep's stock been impacted by COVID-19 (Coronavirus)?

Immutep's stock was trading at $2.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMMP shares have increased by 29.1% and is now trading at $2.75.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for IMMP?

2 Wall Street analysts have issued 12 month price targets for Immutep's shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Immutep's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 154.5% from the stock's current price.
View analysts' price targets for Immutep
or view top-rated stocks among Wall Street analysts.

Who are Immutep's key executives?

Immutep's management team includes the following people:
  • Mr. Marc Voigt, CEO, CFO, Chief Bus. Officer & Exec. Director (Age 48)
  • Ms. Deanne Miller, COO, Gen. Counsel & Joint Company Sec. (Age 44)
  • Dr. Frederic Triebel, Chief Scientific Officer & Chief Medical Officer (Age 66)
  • Ms. Indira Naidu, Joint Company Sec.
  • Mr. Christian Mueller, Director of Clinical Devel. & Regulatory Affairs
  • Mr. Shengfei Fang, Fin. Director & Assistant Company Sec.

Who are some of Immutep's key competitors?

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include CHF Solutions (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

Who are Immutep's major shareholders?

Immutep's stock is owned by many different institutional and retail investors. Top institutional shareholders include HighTower Advisors LLC (0.09%) and Verition Fund Management LLC (0.04%).

Which institutional investors are buying Immutep stock?

IMMP stock was purchased by a variety of institutional investors in the last quarter, including HighTower Advisors LLC, and Verition Fund Management LLC.

How do I buy shares of Immutep?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immutep's stock price today?

One share of IMMP stock can currently be purchased for approximately $2.75.

How much money does Immutep make?

Immutep has a market capitalization of $134.10 million and generates $4.92 million in revenue each year.

What is Immutep's official website?

The official website for Immutep is www.immutep.com.

Where are Immutep's headquarters?

Immutep is headquartered at LEVEL 12 95 PITT STREET, SYDNEY C3, 2000.

How can I contact Immutep?

Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at 61-2-8315-7003 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.